Pharmacogenetics

ARUP offers an extensive pharmacogenetic test menu to help the clinician in identifying appropriate treatment and to monitor efficacy and toxicity by evaluating the genetic differences in metabolic pathways for each individual.
  • Medical Director, Molecular Hematopathology
    Medical Director, Hematopathology
    Co-Scientific Director, NGS and Biocomputing
    Dr. Kelley is an associate professor in the Department of Pathology at the University of Utah. He received his MS in immunology and microbiology and his MD from Ohio State University, and completed his residency in anatomic and clinical pathology and fellowship training in hematopathology at the Cleveland Clinic. He is board certified in anatomic and clinical pathology by the American Board of Pathology, with subspecialty certification in hematology. His research interests include the identification of novel diagnostic and prognostic biomarkers in leukemia and lymphoma.
  • Medical Director, Molecular Genetics and Genomics
    Medical Director, Pharmacogenomics
    Dr. Lyon is a professor of pathology at the University of Utah School of Medicine. She received her PhD in medical genetics from the University of Alabama at Birmingham and continued with fellowship training in clinical molecular genetics at the University of Utah. She is certified by the American Board of Medical Genetics and Genomics in that specialty. Dr. Lyon’s clinical laboratory responsibilities include quality assurance, review of technical assays, and interpretation of results in the context of the clinical indications. In addition to her clinical service, she is involved with research and development in human genetics—validating methods for mutation detection under CLIA requirements and transferring them to the clinical laboratory. Dr. Lyon has focused her interest in combining sequence variants with symptoms, family history, and other evidences to determine clinical significance. She participated in the ACMG/AMP/CAP Standards and Guidelines for the Interpretation of Sequence Variants. In 2014, she was the president of the Association for Molecular Pathology. She is also a member of the board of the American College of Medical Genetics and Genomics (ACMG).
  • Section Chief, Molecular Genetics and Genomics
    Dr. Mao is a professor of pathology and co-director of the Clinical Molecular Genetics Fellowship Program at the University of Utah School of Medicine. She received her MD from Capital University of Medicine in Beijing, China and her MS in molecular pathology from Beijing Union Medical College. She is board certified by the American Board of Medical Genetics and Genomics, with a subspecialty in clinical molecular genetics, and certified with the New York State Department of Health, with a subspecialty in genetic testing. She is a member of several professional societies, including American College of Medical Genetics and Genomics, Association for Molecular Pathology, and American Society of Human Genetics. Her research interests include the genotype-phenotype correlations in inborn errors of metabolism and genetic diseases in the RAS/MAPK pathway; she is also involved with implementing next-generation sequencing techniques into molecular diagnostics.
  • Medical Director, Toxicology
    Medical Director, Pharmacogenetics
    Dr. McMillin is a professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology and toxicology from the University of Utah and is certified by the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry. She is a member of ARUP’s R&D Executive Committee, and is actively involved in professional associations such as the International Association of Therapeutic Drug Monitoring and Clinical Chemistry (IATDMCT), the American Association for Clinical Chemistry (AACC), and the College of American Pathologists (CAP).Her primary interests include detection of neonatal drug exposures, pain management, and clinical applications and implementation of pharmacogenomics.
  • Chief Executive Officer, ARUP Laboratories
    Dr. Perkins is the CEO of ARUP Laboratories and a professor of pathology at the University of Utah School of Medicine. Dr. Perkins has been with ARUP and the University of Utah for over 25 years. During this time, she has served in numerous leadership roles, including director of hematopathology, interim department chair, division chief of clinical pathology, director of the ARUP R&D Institute, and, for the past 10 years, member of the ARUP Laboratories' executive management team. She is a tenured professor at the University of Utah School of Medicine, is board certified in anatomic pathology, and holds a special qualification in hematology. She has authored over 200 peer-reviewed journal articles and 70 book chapters in hematopathology. She received her PhD in biochemistry from the University of Miami, and earned her MD and completed her pathology residency at Washington University in St. Louis. She completed her hematopathology fellowship under Dr. Carl Kjeldsberg at the University of Utah.
  • Chief, Hematopathology
    Director, Hematopathology Fellowship Program
    Dr. Salama is professor of pathology, chief of hematopathology, and director of the Hematopathology Fellowship Program at the University of Utah School of Medicine. Dr. Salama received his MD from Cairo University and completed a hematopathology fellowship at the University of New Mexico and a surgical pathology fellowship at Stanford University. He is certified by the American Board of Pathology in anatomic pathology and hematopathology. His areas of interest span all aspects of hematopathology, including morphology, specialized studies of bone marrow and lymph node, and digital pathology.
  • Medical Director, Anatomic Pathology
    Dr. Samowitz is a professor of pathology at the University of Utah School of Medicine. He received his MD from SUNY Downstate, and completed residency training in anatomic pathology at the University of Chicago and fellowships in gastrointestinal pathology at Johns Hopkins Hospital. Specializing in gastrointestinal pathology and the molecular genetics of colorectal cancer, Dr. Samowitz is also the medical director for numerous molecular tests in solid tumor molecular diagnostics, including single-gene assays and next-generation sequencing panels.